Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Trial in Solid Tumours, Expanding HK Biotech Pipeline

The Quick Take

• Akeso (9926.HK) received clearance for its AK157D1 B7-H3 antibody-drug conjugate to begin Phase I trials.
• AK157D1 targets solid tumours using next-generation ADC technology, representing a third differentiated clinical asset.
• The Phase I clearance advances Akeso's position as a leading China-based biotech with growing oncology pipeline depth.

Akeso's receipt of clinical trial clearance for AK157D1—a B7-H3-targeting next-generation antibody-drug conjugate—adds a third meaningful clinical asset to the Hong Kong-listed biotech's rapidly expanding pipeline. B7-H3 is a validated oncology target expressed across a broad range of solid tumours, and the ADC therapeutic modality is currently among the most actively invested platforms in global cancer drug development. The clearance to enter Phase I trials positions AK157D1 alongside Akeso's established clinical programmes, extending the company's oncology pipeline depth beyond its anti-PD-1 checkpoint franchise.

The market implication for HK-listed biotech is that Akeso's Phase I clearance reinforces the company's status as a pipeline-rich clinical-stage asset attracting attention from global pharma partnership scouts. ADC technology has attracted extraordinary M&A and licensing interest in 2024-2026, with deals like AstraZeneca-Daiichi Sankyo and Pfizer-Seagen setting precedent for multi-billion-dollar partnerships. Akeso's AK157D1 entry into Phase I broadens its licensing option set at a time when Western pharma companies are actively building their ADC portfolios through Asia-Pacific licensing deals.

The critical watch item is the Phase I dose-escalation data readout for AK157D1, expected within 12-18 months. Safety and tolerability data will be the gating factor for whether the B7-H3 ADC programme advances or joins the significant population of Phase I ADC programmes that fail on tolerability. The macro variable is the global ADC competitive landscape: as more companies advance B7-H3 ADC candidates into trials, differentiation on dosing schedule, payload selectivity, and tumour penetration will determine which assets command partnership interest.

Synthesized from 1 source.